Drugmakers try evasion, tougher negotiations to fight new U.S. insurer tactic

In the escalating battle over U.S. prescription drug prices, major pharmaceutical companies are scrambling to limit the economic damage from a new U.S. insurer tactic that coaxes patients away from expensive drugs.